

Carboxylic Acid (Bio)Isosteres in Drug Design

Carlo Ballatore,* Donna M. Huryn, and Amos B. Smith, III^[a]

The carboxylic acid functional group can be an important constituent of a pharmacophore, however, the presence of this moiety can also be responsible for significant drawbacks, including metabolic instability, toxicity, as well as limited passive diffusion across biological membranes. To avoid some of these shortcomings while retaining the desired attributes of the carboxylic acid moiety, medicinal chemists often investigate the use of carboxylic acid (bio)isosteres. The same type of strategy can also be effective for a variety of other purposes, for example, to increase the selectivity of a biologically active compound or to create new intellectual property. Several carboxylic acid isosteres have been reported, however, the outcome of any iso-

steric replacement cannot be readily predicted as this strategy is generally found to be dependent upon the particular context (i.e., the characteristic properties of the drug and the drug–target). As a result, screening of a panel of isosteres is typically required. In this context, the discovery and development of novel carboxylic acid surrogates that could complement the existing palette of isosteres remains an important area of research. The goal of this Minireview is to provide an overview of the most commonly employed carboxylic acid (bio)isosteres and to present representative examples demonstrating the use and utility of each isostere in drug design.

Introduction

The carboxylic acid functional group plays a cardinal role in the biochemistry of living systems as well as in drug design. A wide variety of endogenous substances, such as amino acids, triglycerides and prostanooids, possess the carboxylic acid moiety. Furthermore, this functional group is often part of the pharmacophore of diverse classes of therapeutic agents.^[1] Indeed, a large number (>450) of carboxylic acid-containing drugs have been marketed worldwide, including widely used nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotics, anticoagulants, and cholesterol-lowering statins, among others. The acidity, combined with the ability to establish relatively strong electrostatic interactions and hydrogen bonds, is the reason this functional group is often a key determinant in drug–target interactions. However, despite the success of carboxylic acid drugs, the presence of a carboxylic acid residue in a drug or a drug candidate can represent a liability. For instance, a diminished ability to passively diffuse across biological membranes can raise a significant challenge, particularly in the context of central nervous system (CNS) drug discovery, where the blood–brain barrier (BBB) can be relatively impermeable to negatively charged carboxylates.^[2] Furthermore, idiosyncratic drug toxicities arising from the metabolism of the carboxylic acid moiety (e.g., glucuronidation)^[3] have been linked to withdrawals of marketed drugs.^[4] Thus, to avoid these and other possible shortcomings, the replacement of the carboxylic acid functional group with a suitable surrogate, or (bio)isostere, can represent an effective strategy.

The concept of bioisosterism is based on the notion that single atoms, groups or whole molecules that exhibit similar volume, shape, and/or physicochemical properties can produce broadly similar biological effects.^[5] However, as occasionally observed, isosteric replacements can result in derivatives that exhibit different or even opposite pharmacology relative to the parent carboxylic acids. The outcome of any isosteric replacement cannot be accurately predicted, however, the physicochemical properties of both the isostere and the corresponding binding partner(s) in the biological system are often a key factor. In addition to the acidity of the carboxylic acid surrogate, several other parameters, such as size, shape, charge distribution and lipophilicity, play important roles. The relative importance of each of these properties depends on the particular context considered. Thus, for instance, whereas lipophilicity of the isostere might be one of the most important properties when designing analogues for improved passive diffusion across biological membranes, geometry and charge distribution of the acidic moiety can be critical aspects if the carboxylic acid isostere is required to establish two-point interactions with an arginine side chain in the binding site. Several carboxylic acid surrogates have been reported that display utility in drug design (Figure 1). Herein, we summarize the key properties and provide representative examples describing the use of each of the carboxylic acid (bio)isosteres in drug design.

Hydroxamic Acids

Hydroxamic acids exhibit moderately acidic characteristics, with pK_a values in the range of ~8–9,^[6] and strong metal-chelating properties.^[7] This functional group is found in a variety of natural products^[8] and in a number of biologically active compounds.^[9] Although hydroxamic acids are most commonly

[a] Dr. C. Ballatore, Prof. D. M. Huryn, Prof. A. B. Smith, III
Department of Chemistry
University of Pennsylvania
231 South 34th St., Philadelphia PA, 19104 (USA)
E-mail: bcarlo@sas.upenn.edu




Figure 1. Representative examples of a) acyclic and b) cyclic carboxylic acid bioisosteres and their corresponding predicted logD values as determined using Pipeline Pilot version 8.0 (Accelrys, Inc., San Diego, USA).


employed in drug design for their metal-chelating properties,^[7] this functional group has also been employed successfully as a carboxylic acid bioisostere. Deprotonation of the hydroxamic acid moiety can lead either to the N or to O anion (Scheme 1),^[10] depending on the nature of the substituents and solvent.^[6,11] In polar solvents, and at physiological conditions, deprotonation of the hydroxamic acid yields both the N and O anions. In vivo, hydroxamic acids can undergo relatively rapid hydrolysis^[12] to the corresponding carboxylic acids, although the stability of these compounds towards hydrolysis can be significantly improved by introducing relatively large substituents at the nitrogen atom of the hydroxylamine fragment.^[13] Such modifications would also prevent the formation

of the N anion. In addition, like carboxylic acids, hydroxamic acids can be metabolized via sulfation and glucuronidation, which ultimately could lead to the formation of toxic chemically reactive metabolites.^[14] Recent examples of hydroxamic acids and esters employed as carboxylic acid bioisosteres include benzhydroxamic acids and esters as MAP/ERK kinase (MEK) inhibitors^[15] that exhibit favorable activity profiles in the biochemical and cellular assays, as well as acceptable absorption, distribution, metabolism, and excretion (ADME)/pharmacokinetic (PK) properties (e.g., **3** and **4**; Table 1).

Phosphonic and Phosphinic Acids

The main characteristics of both phosphonic and phosphinic acids are the relatively high acidity, pK_{a1} value of ~1–3, and their nonplanar geometries.^[17] Compared with carboxylic acids, these acidic moieties are more polar, thus these isosteres usually lead to a lowering of the partition coefficient (logP).^[17] The use of these acidic moieties as replacements of the carboxylic acid functional group has been exploited successfully in the design of analogues of neurotransmitters γ -aminobutyric acid (GABA, **5**) and glutamic acid (**6**) (Figure 2).^[16,18] In many cases, while the affinity of the isosteric analogue is generally equivalent

to that of the parent carboxylic acid compound, the intrinsic activity, however, is changed. One such example includes phaclofen (**7**),^[19] the phosphonate derivative of the GABA agonist



Scheme 1. Deprotonation equilibrium of hydroxamic acid, and the tautomerisation between the N and O anion.

Table 1. Comparison of hydroxamate and carboxylate MAP/ERK kinase inhibitors in a cell-free kinase cascade assay.^[15]



			
Compd	X	R	IC ₅₀ [nM]
1	OH	H	15
2	OH	F	5.8
3	NHOH	H	7.9
4	NHOCH ₂ ^t Pr	F	7.0

Table 2. Inhibition of binding of [³H]baclofen to GABA_B receptors (cat cerebellum) and [³H]muscimol to GABA_A receptors (rat cortex).^[16]

Compd	R	IC ₅₀ [μM]	
		GABA _B	GABA _A
GABA (5)	–	0.025	0.128
9	H	0.0024	1.7
10	Me	0.0066	inactive

that, like phaclofen (7), exhibit GABA receptor antagonist properties.^[21] Other notable examples of sulfonic acids being employed as carboxylic acid isosters include derivatives of the cholecystokinin-B (CCK-B) receptor antagonist 13. Whereas planar, heterocyclic carboxylic acid bioisosteres (e.g., 3-hydroxy-isoxazole 14) exhibited similar activity to 13, sulfonic acid analogue 15 was the only derivative bearing a nonplanar carboxylic acid isostere to produce low nanomolar IC₅₀ values (cf., 15, 16, and 17; Table 3).^[22]


**Figure 2.** The structures of GABA, glutamic acid and selected analogues.

baclofen (8). In this case, while baclofen is a GABA_B agonist, phaclofen (7) acts as an antagonist. In the case of mono- or dialkylphosphonic acid derivatives of GABA, however, isosteric replacement of the carboxylic acid moiety resulted in highly potent agonists (e.g., 9, and 10; Table 2) that, unlike the natural ligand (GABA), are selective for GABA_B receptors.^[16] Similar outcome was observed for some glutamic acid derivatives, such as L-AP4 (11; Figure 2), which selectively activate the group III metabotropic glutamate receptors (mGluR).^[18]

Sulfonic and Sulfinic Acids


Like phosphonic acids, sulfonic and sulfinic acids are nonplanar as well as both more polar and acidic ($pK_a < 1$) than carboxylic acids. Amino acids analogues bearing either sulfonic or sulfinic acids have been found to be relatively potent activators of the glutamate receptors.^[20] Moreover, sulfonate derivatives of baclofen (8), such as saclofen (12; Figure 2), have been reported

Table 3. Comparison of sulfonic and carboxylic acid CCK-B receptor antagonists.^[22]

Compd	X	IC ₅₀ [nM]		pK_a
		CCKB	CCKA	
13	CH ₂ COOH	1.7	4500	5.6
15	CH ₂ SO ₃ Na	1.3	1010	< 1
14		2.6	1700	6.5
16	CH ₂ P(O)(OH) ₂	23	2700	3.4, 7.8
17	CH ₂ P(O)(OH)Me	23	4400	3.7

Sulfonamides, Acylsulfonamides, and Sulfonylureas

Sulfonamides were among the first examples of carboxylic acid isosteres to show utility in drug design. Classical examples of this type of carboxylic acid surrogate include the sulfonamide class of antibacterial agents developed in the 1930s and 40s, such as sulfadiazine (18) and sulfanilamide (19), the active form of prontosil (20).^[23] Compounds of this class work by inhibiting tetrahydropteroate synthetase. The similarities between the sulfanilamide anion in 19 and the carboxylate of the natural substrate, *para*-aminobenzoic acid (PABA; 21) were found to be critical to the bacteriostatic properties of the sulfanilamides.^[24] Although nonplanar and generally only weakly



acidic ($pK_a \approx 10$)^[17] compared with PABA ($pK_a \approx 6.5$), the sulfonamide moiety can in fact establish a similar geometry of hydrogen bonds compared with carboxylic acids as the distance between the two oxygen atoms is similar to that found between the two oxygen atoms of a carboxylate. Furthermore, incorporation of appropriate substituents can lower the pK_a value of the sulfonamide moiety to a value essentially equal to that of PABA, for example, sulfadiazine (18) that exhibits a pK_a value of approximately 6.5.

In addition to sulfonamides, acylsulfonamides (also known as sulfonimides) and sulfonylureas have been used extensively as carboxylic acid surrogates. The pK_a values of acylsulfonamides and sulfonylureas fall within the range of carboxylic acids (4–5).^[25] Notable examples include several cysteinyl leukotriene (LTE_4) receptor antagonists, such as compounds 22 and 23 (Table 4), which exhibit improved activity compared

Table 4. Antagonists of the cysteinyl leukotriene (LTE_4) receptor.^[26]

Compd	X	Concn [μ M]	Inhibition [%]	pK_d [b]
24	COOH	3.3	100	6.6
25		1	50	6.6
22	CONHSO ₂ Ph	0.1	100	8.6
23	CONHSO ₂ nBu	1.0	100	–

[a] Inhibition of LTE_4 . [b] pK_d determined in guinea pig tracheal spirals using LTE_4 as an agonist.


with the parent carboxylic acid (24) and other derivatives bearing commonly used carboxylic acid bioisosteres, such as tetrazole (25).^[26] Other interesting examples were reported by scientists at GlaxoSmithKline where replacement of the carboxylic acid moiety of β_3 -adrenergic receptor agonist 26 (Table 5) led to derivatives (27–29) with higher potency and greater functional selectivity for the β_3 -adrenergic receptor.^[27]

Table 5. Stimulation of cAMP accumulation in CHO cells expressing human β_3 , β_2 , and β_1 adrenergic receptors by acylsulfonamides and sulfonylureas.^[27]

Compd		β_3	pEC_{50} β_2	β_1
26		7.8	7.3	7.1
27		8.3	7.7	7.0
28		9.1	7.5	6.1
29		7.8	6.6	6.4

2,2,2-Trifluoroethan-1-ol and Trifluoromethylketones

Highly fluorinated alcohols and ketones comprise viable carboxylic acid bioisosteres. For example, 2,2,2-trifluoroethan-1-ol is a weakly acidic ($pK_a \approx 12$), nonplanar carboxylic acid bioisostere (Scheme 2). The most interesting feature of this carbox-






Scheme 2. Structure of carboxylic acid bioisosteres based on fluorinated alcohol and ketones. In the latter case, it is the hydrate form, which is present under physiological conditions, that is bioisosteric with the carboxylic acid moiety.

ylic acid surrogate is the relatively high lipophilicity, which makes this moiety potentially attractive for CNS drug discovery programs, where the presence of a carboxylic acid moiety in a drug candidate can result in a limited rate of passive diffusion across the BBB.^[2] Similar overall properties can be ascribed to the trifluoromethylketone moiety. Under aqueous physiological conditions, this functional group is in equilibrium with the hydrate form, with the latter being bioisosteric with the carboxylic acid moiety (Scheme 2).

An interesting case study comparing these two carboxylic acid surrogates was reported by scientists at Merck in the

Table 6. Examples of EP1 receptor antagonists bearing a carboxylic acid or 2,2,2-trifluoroethan-1-ol or trifluoro-methylketone hydrate isostere.^[28]


Compd	X	$K_i^{[a]}$ [nM]	B/P ^[b]	$t_{1/2}^{[c]}$ [h]
30		3	–	< 1
31		3	–	1
32		4	1	2

[a] EP₁ inhibitory constant. [b] Brain/plasma (B/P) ratio. [c] Half-life ($t_{1/2}$) in rat.

design of brain-penetrant prostaglandin E receptor 1 (EP1) antagonists. Whereas carboxylic acid **30** (Table 6) was potent in the functional assay, this and other related carboxylic acid-containing analogues exhibited limited brain penetration as well as short half-lives in plasma.^[28] Replacement of the carboxylic acid moiety with either the 2,2,2-trifluoroethan-1-ol or the trifluoromethylketone moiety led to derivatives **31** and **32**, respectively (Table 6) that retain excellent binding affinity for the EP₁ receptor, but exhibit favorable ADME/PK properties including oral bioavailability and brain penetration.^[28]

Tetrazoles

Tetrazoles are amongst the most commonly employed carboxylic acid isosteres; for recent Review articles, see Herr et al.^[29] and Myznikov et al.^[30] The 5-substituted tetrazoles exist in equilibrium between the 1*H* and the 2*H* tautomers (Scheme 3).


**Scheme 3.** Tautomers of 5-substituted tetrazoles.

The most important features of the tetrazolic acids are the planarity and acidity, which closely resemble those of carboxylic acids ($pK_a = \sim 4.5\text{--}4.9$).^[17,31] However, relative to carboxylic acids, tetrazoles are slightly larger.^[32,33] Moreover, analysis of crystal structures and computational studies indicate that the hydrogen-bond environment surrounding the tetrazolates extends further than in the case of carboxylates.^[33] In addition, tetrazolate anions are more lipophilic than the corresponding carboxylates,^[34] and compared with the latter, they exhibit slightly different electrostatic potential^[35] and charge distribution due to the delocalization of the negative charge over the five-membered ring system. Interestingly, experimental evi-

dence suggests that tetrazoles, like carboxylic acids, are capable of forming two-point interactions with amidines.^[36] However, the stability of the tetrazolate–amidine complex is found to be lower than the corresponding carboxylate–amidine salt.^[36] Metabolically, tetrazoles can also undergo N-glucuronidation,^[3] however, these adducts are not as chemically reactive as the O-glucuronides derived from carboxylic acids and hydroxamic acids and, therefore, have not been linked to toxic effects in humans.

In drug design, the most important examples showcasing the utility of tetrazoles as carboxylic acid isosteres include several nonpeptidic angiotensin II type 1 (AT1) receptor antagonists.^[37] The AT1 receptor is a member of the G protein-coupled receptor (GPCR) superfamily that plays an important role in vasoconstriction.^[38] In a series of *N*-(biphenylmethyl)imidazole AT1 receptor antagonists, where both carboxylic acid **33** and several bioisosteres (**34–37**) exhibited potent biological activity in vitro, only the tetrazole derivative, losartan (**38**), was found to be effective after oral administration (Table 7).^[39] Interestingly, site-directed mutagenesis and model-

Table 7. AT1 receptor antagonist and in vivo activities of carboxylic acid **33** and a series of related isosteres.^[39]

Compd	X	pK_a estimated	$IC_{50}^{[a]}$ [μ M]	Dose ^[b] [$mg\ kg^{-1}$]	
				iv	po
33	COOH	5	0.23	3	11 ^[c]
34	CONHOH	10.5	4.1	3	> 30 ^[d]
35	CONHOCH ₃	10.9	2.9	10	inactive ^[e]
36	CONHSO ₂ Ph	8.4	0.14	> 3 ^[d]	30
37	NHSO ₂ CF ₃	4.5	0.083	10	100
38		5–6	0.019	0.80 ^[c]	0.59 ^[c]

[a] Inhibition of specific binding of [³H]angiotensin II (2 nM) to rat adrenal cortical microsomes. [b] Intravenous (iv) and oral (po) dose at which statistically significant drops in blood pressure were observed (> 15 mm Hg) in renal hypertensive rats. [c] Value given is the effective dose that lowers the blood pressure by 30 mmHg (ED₃₀). [d] At this dose, no statistically significant drop in blood pressure was observed. [e] Compound failed to cause a significant drop in blood pressure even at 100 mg kg^{−1}.

ing studies indicated that the tetrazole moiety of losartan (**38**) and related antagonists occupy the same space within the AT1 receptor as the carboxylic acid terminus of the natural ligand, angiotensin, although the tetrazole ring appears to be involved in more complex sets of interactions with the surrounding amino acid residues, namely Lys 119 and His 256.^[40] Notably, five out of six of the AT1 receptor antagonists used clinically for the treatment of high blood pressure contain a tetrazole moiety.^[39,41]

5-Oxo-1,2,4-oxadiazole and 5-Oxo-1,2,4-thiadiazole

The 5-oxo-1,2,4-oxadiazole and related thiadiazole systems (Figure 1) are planar acidic heterocycles ($pK_a \sim 6-7$),^[42] which, like tetrazoles, have been successfully employed in the synthesis of AT1 receptor antagonists (Table 8).^[43] Interestingly, these heterocycles are reported to be comparatively more lipophilic than the tetrazole; this property led to increased oral bioavailability of potent AT1 receptor antagonists (cf., **39**, **40**, and **41**; Table 8).^[43]

Thiazolidinedione, Oxazolidinedione, and Oxadiazolidine-dione

The thiazolidinedione heterocycle (Figure 1) comprises a planar, moderately acidic ($pK_a \sim 6-7$), and relatively lipophilic carboxylic acid isostere.^[44] This heterocycle is found in several potent agonists of the peroxisome proliferator activated receptor γ (PPAR γ) that are used for the treatment of noninsulin-dependent type 2 diabetes mellitus (e.g., pioglitazone (**42**); Figure 3).^[45] Since several endogenous compounds, as well as drug candidates that are known to activate PPAR γ , are carboxylic acids,^[46] it seems likely that the thiazolidinedione moiety of the "glitazone" drugs are likely acting as carboxylic acid surrogate. Thiazolidinediones and related heterocycles have also been employed as carboxylic acid bioisosteres in the design of GPR40 agonists (e.g., **43-46**; Figure 3).^[47] GPR40 is a GPCR that enhances insulin secretion when activated by naturally occurring, medium- to long-chain fatty acids (FFA),^[48] or by synthetic carboxylic acid compounds, such as several aryl propionic acids derivatives.^[49]





Figure 3. Biologically active thiazolidinedione-containing compounds.

Table 8. Inhibitory effects on the specific binding of [¹²⁵I]AT1 and AT1-induced pressor responses in rats.^[43]

Compd	X	Properties of X pK_a log P	BA ^[a] [%]	IC ₅₀ ^[b] [μ M]	Inhibition ^[c] [%] 3 h/7 h
39		5.3 0.32	5	0.11	100/92
40		6.1 0.9	20	0.42	100/100
41		6.6 1.58	51	0.25	100/100

[a] Oral bioavailability (BA). [b] Receptor affinity as determined by the inhibition of specific binding of [¹²⁵I]AT1 (0.2 nM) to bovine adrenal cortex. The IC₅₀ value is the concentration of compound which inhibits [¹²⁵I]AT1 binding by 50%. [c] Percent inhibition of AT1 (0.1 μ g kg⁻¹ iv)-induced pressor response at 3 and 7 h after administration of the test compounds (1 mg kg⁻¹ po) in conscious male Sprague-Dawley rats.

Metabolically, the thiazolidinedione ring is hypothesized to undergo oxidative cytochrome P450 (CYP450)-mediated ring opening (Scheme 4),^[3] which could in turn lead to the formation of electrophilic metabolites thereby causing idiosyncratic



Scheme 4. Cytochrome P450-mediated oxidation and ring opening of the thiazolidinedione heterocycle.

adverse reactions.^[50] Indeed, the first marketed thiazolidinedione drug, troglitazone, was withdrawn from the market because of numerous reports of liver failure that might have been caused, at least in part, by bioactivation of the thiazolidinedione ring. Similar problems, however, have not been observed with other glitazones.

3-Hydroxyisoxazole and 3-Hydroxyisothiazole

The 3-hydroxy derivative of isoxazole and the corresponding isothiazole (Figure 1) are planar carboxylic acid isosteres that exhibit pK_a values of $\sim 4-5$. The 3-hydroxyisoxazole heterocycle is found in naturally occurring amino acids, such as ibotenic acid (**47**; Figure 4), which is an agonist of the *N*-methyl-D-aspartic acid (NMDA) receptor.^[51] This type of carboxylic acid bioisostere has been employed extensively in the development




Figure 4. Examples of 3-hydroxyisoxazoles.

of several potent derivatives of GABA and glutamate^[51] neurotransmitters.

As summarized in Figure 4, a number of agonists of GABA receptors, such as muscimol (**48**),^[52] and 4,5,6,7-tetrahydroisoxa-zolo[5,4-c]pyridin-3-ol (THIP, **49**),^[53] as well as antagonists (e.g., **50**) have been developed.^[54] In addition, among 3-hydroxyisoxazole-containing glutamate analogues are agonists and antagonists of the ionotropic glutamate AMPA receptor, such as compounds **51–53** (Figure 4),^[51] while examples of 3-hydroxyisothiazole-containing glutamate derivatives include NMDA receptor agonist **54** (Figure 4), an isothiazole derivative of the naturally occurring ibotenic acid.^[55]

Substituted Phenols

Although unsubstituted phenols are weakly acidic ($pK_a \approx 9.9$), the appropriate choice of electron-withdrawing substituents can lower the pK_a values to within or even below the range of aliphatic carboxylic acids.^[56] Representative examples include 2,6-difluorophenols ($pK_a \approx 7.1$),^[57] which have been employed as lipophilic bioisosteres of the carboxylic acid in the design of competitive inhibitors of GABA aminotransferase (e.g., **55** and **56**; Figure 5) that exhibit comparable binding affinity for the enzyme as the natural substrate (GABA).^[58] The same bioisostere has been employed to obtain potent noncarboxylate aldose reductase inhibitors (cf., **57** and **58**; Table 9).^[59]

Squaric Acid

Squaric acid (**59**), a planar, diprotic four-membered ring oxocarbon, exhibits remarkable acidity (i.e., $pK_{a1} = 0.5$, $pK_{a2} = 3.5$).^[56] Although the acidity of squaric acid, like that of other cyclic polyones, such as tetroneic acid or the cyclopentane-1,3-diones (see below), can be explained at least in part by the





Figure 5. 2,6-Difluorophenol-containing GABA aminotransferase inhibitors.

Table 9. Aldose reductase inhibitory activity of a noncarboxylate derivative (**58**) compared with the carboxylic acid (**57**).^[58]

Compd	Structure	IC ₅₀ [μ M]
57		1.9
58		0.4

principle of vinylogy,^[60,61] in the case of the squaric acid and related oxocarbons, the 2π -pseudoaromaticity of the ring system is believed to contribute to the stabilization of the doubly deprotonated form (Scheme 5).^[62] Derivatives of squaric



Scheme 5. Squaric acid (**59**), squaramide (**60**), and the general structures of related compounds.


acids, particularly squaramides (e.g., **60**), have been exploited as bioisosteres of the carboxylic acid and phosphate^[63] moieties. An interesting application of this bioisostere was reported by Kinney and co-workers, who developed NMDA receptor antagonists, such as **61**^[64] and **62**^[65] (Table 10), in which the squaramide moiety was used to mimic the α -amino acid moiety of phosphonate **63** and glutamic acid.^[64]

Table 10. NMDA affinity (IC_{50}) and in vivo efficacy as determined by NMDA-induced lethality (ED_{50}) of selected phosphonoalkyl-3,4-diamino-3-cyclobutene-1,2-dione derivatives.^[64, 65]


Compd	Structure	IC_{50} [μ M]	ED_{50} [mg kg ⁻¹]
63		0.39	38
61		0.47	29
62		0.03	2.1

3- and 4-Hydroxyquinolin-2-ones

Notable examples of bioisosterism with the carboxylic acid moiety have been reported for series of 3- and 4-hydroxyquinolin-2-ones.^[66–68] Although considerably less acidic than carboxylic acids ($pK_a=8.7$), scientists at Pfizer discovered that 3-hydroxyquinolin-2-one-containing D-amino acid oxidase inhibitors can in fact establish hydrogen-bonding interactions within the enzyme active site, in a very similar fashion as carboxylic acid-containing inhibitors (cf., **64** and **65**; Figure 6).^[68] Exam-

**Figure 6.** Schematic representation of hydrogen-bonding interactions of carboxylic acid **64** and hydroxyquinolin-2-one **65** within the binding site of D-amino acid oxidase.

ples of 4-hydroxyquinolin-2-ones as carboxylic acid isosteres have been reported by scientists at Merck with a series of potent NMDA antagonists with improved brain penetration.^[66, 67] Although effective in vitro, 5-iodo-7-chlorokynurenic acid (**66**) and related analogue **67** exhibit limited brain pene-

5-Iodo-7-chlorokynurenic acid (**66**)**67****Table 11.** NMDA receptor activities of 3'-substituted-4-hydroxy-2-quinolones.^[65]


Compd	R	$IC_{50}^{[a]}$ [nM]	$ED_{50}^{[b]}$ [mg kg ⁻¹]
68		14	> 250
69		4	> 100
70	Ph	170	7.6
66		4.5	3.9
67		2.2	0.9

[a] Inhibition of the binding of [³H]-4 to the strychnine-insensitive glycine site on rat brain membranes. [b] Protection from audiogenic seizure in DBA/2 mice (21–23 days old, weighing 5–9 g) after oral administration of test compounds.

tration, and thus could not be considered as potential candidates for the treatment of CNS diseases. By, replacement of the carboxylic acid with vinylogous-type acids of noncarboxylated 4-hydroxyquinolin-2-ones (**66–68**), a series of NMDA antagonists with potent binding affinity as well as improved brain penetration resulted (Table 11).^[66]

Tetronic and Tetramic Acids

Tetronic (**71**) and tetramic (**72**) acids are naturally occurring acidic heterocycles.^[70] Despite the similar structure, the two heterocycles exhibit markedly different acidity. Whereas **71** is considerably acidic with a pK_a value of ~ 3.8 , the corresponding pyrrolidine-2,4-dione (i.e., tetramic acid) exhibits a pK_a value of ~ 6.4 .^[71] This difference has been explained by the fact that tetronic acid exists predominantly in the enol tautomeric form (**71 B**; Scheme 6) and, as such, behaves more as an oxoacid, whereas the tautomeric equilibrium of tetramic acid is believed to be shifted more towards the di-oxo tautomer (**72 A**; Scheme 6), leading this heterocycle to exhibit pK_a values of a carbon acid.^[56]

**Scheme 6.** The keto–enol tautomerisation of tetronic (**71**) and tetramic (**72**) acids.

Although tetronic and tetramic acids are found in numerous biologically active compounds, their use as carboxylic acid isosteres is not particularly common. Examples include a series of tetramic acid-containing NMDA antagonists (e.g., **73**; Table 12)

Table 12. NMDA antagonist activity of tetramic acid derivative 73 . ^[69]		
Structure	IC ₅₀ ^[a] [μ M]	K _d ^[b] [μ M]
	0.7	6.15
[a] Inhibition of the binding of [³ H]-L-689,560 to the strychnine insensitive glycine site on rat brain membranes. [b] Inhibition of NMDA-induced depolarizations in rat cortical slices.		

that were designed based on the same pharmacophore model used in the design of 3'-substituted-4-hydroxy-2-quinolones described above (Table 11). Other studies also reported tetronic and tetramic acid-containing derivatives of known NSAIDs as γ -secretase modulators with in vitro activities comparable to the parent carboxylic acid compound.^[72]

Cyclopentane-1,3-diones

Related to tetronic and tetramic acids, cyclopentane-1,3-diones (e.g., **74**; Scheme 7) exist as rapidly exchanging enol-ketone tautomers.^[73] As such, consistent with the principle of vinylogy,^[61] 1,3-diones exhibit pK_a values that fall within the range of carboxylic acids.^[73] The characterization of the cyclopentane-



Scheme 7. Enol-ketone tautomers of cyclopentane-1,3-dione **74**.

1,3-diones as potential bioisosteres of the carboxylic acid moiety was recently demonstrated for the first time in our laboratory.^[74] Evaluation of physicochemical properties revealed that, in addition to the intrinsic acidity, the cyclopentane-1,3-dione unit, like carboxylic acids, can form relatively stable 1:1 salt complexes with amidines.^[74] Furthermore, a series of derivatives of the known thromboxane A₂ (TP) receptor antagonist, **75**,^[75] in which the carboxylic acid moiety is replaced by a mono or di-substituted cyclopentane-1,3-dione unit, resulted in TP receptor antagonists with IC₅₀ values in the nanomolar range against human and mouse TP receptors (e.g., compounds **76**, **78**, and **79**; Table 13).^[74] A unique aspect of the cyclopentane-1,3-dione unit is that it presents multiple points of attachment, which can be exploited to impart alternative orientations of the bioisostere (cf., **76** and **77**; Table 13) and/or to diversify the structure of the acidic moiety.

Table 13. Thromboxane A₂ (TP) receptor antagonist activity of cyclopentane-1,3-dione derivatives.^[74]

Compd	X	IC ₅₀ ^[a] [nM]	
		mouse	human
75		27	61
76		52	250
77		> 10 000	> 10 000
78		3.1	131
79		5.8	41
[a] Results of an IP ₁ assay using mouse or human TP receptor.			


Other Potential Bioisosteres

In addition to the isosteres discussed above, several other cyclic and acyclic structures, including boronic acids, mercaptoazoles, and sulfonimidamides, might be useful bioisosteres of the carboxylic acid moiety. The boronic acid moiety, for example, which is found in a number of biologically active compounds,^[76] is likely to establish hydrogen bonds of similar geometries as carboxylic acids despite the limited acidity of this functional group (pK_a = ~9–10). Likewise, mercaptoazoles (e.g., **80–91**; Table 14),^[77] which, depending on the oxidation state of the sulfur atom, can exhibit relatively wide ranges of acidity,

Table 14. Acidity of a series of mercaptoazoles.^[77]

Compd	n	X Y Z			pK _a
		X	Y	Z	
80	0	CH	CH	N	11.6
81	1	CH	CH	N	9.8
82	2	CH	CH	N	8.67
83	0	N	CH	N	9.5
84	1	N	CH	N	7.38
85	2	N	CH	N	6.23
86	0	N	N	CH	8.2
87	1	N	N	CH	6.09
88	2	N	N	CH	5.15
89	0	CO	NH	N	7.85
90	1	CO	NH	N	5.2
91	2	CO	NH	N	4.79

might also be useful in drug design. Finally, cyclic sulfonimides (e.g., **92**; Scheme 8) have recently been proposed by scientists at AstraZeneca as potential bioisosteres of the carboxylic acid moiety.^[78] The sulfonimide heterocycle exhibits pK_a values of 5–6, and although they can exist in four possible tautomers (Scheme 8), computational studies and X-ray crystal



Scheme 8. The four possible tautomers (A–D) of sulfonimide **92**.

structure data suggest that the most stable tautomer has the acidic proton on the nitrogen in position 2 (**92 A**). The most distinctive feature of this heterocycle is the presence of a stereogenic tetrahedral sulfur atom, as well as an sp^3 carbon that can permit structural differentiation of the acidic moiety. Although there have been no reports of this particular heterocycle being applied successfully to the synthesis of biologically active compounds, the structural and physicochemical properties of this class of heterocycles make them potentially promising carboxylic acid bioisosteres.

Outlook

As highlighted in this Minireview, a diverse set of carboxylic acid bioisosteres have been identified, which exhibit various degrees of similarities with the carboxylic acid moiety in terms of size, geometry, charge distribution, acidity, and lipophilicity. However, as the outcome of any isosteric replacement is typically dependent upon the particular context defined by the physicochemical properties of the isostere and the corresponding binding counterpart(s) in the biological target(s), the availability of an increasingly larger set of potential carboxylic acid surrogates is ultimately critical to the success of the isosteric replacement strategy. Thus, the investigation of new and alternative structures that could complement the existing palette of carboxylic acid surrogates remains an important area of research.

Acknowledgements

The Authors are grateful to Prof. E. Amin and Dr. T.-L. Chiu (University of Minnesota, USA) for providing calculated $\log D$ values.

Financial support for this work has been provided by the US National Institutes of Health (NIH)/National Institute on Aging (NIA) (grant no. AG034140).

Keywords: bioisosteres • carboxylic acids • drug design • isosteric replacement

- [1] P. J. Hajduk, M. Bures, J. Praestgaard, S. W. Fesik, *J. Med. Chem.* **2000**, *43*, 3443–3447.
- [2] H. Pajouhesh, G. R. Lenz, *NeuroRx* **2005**, *2*, 541–553.
- [3] I. Gardner, R. S. Obach, D. A. Smith, Z. Miao, A. A. Alex, K. Beaumont, A. Kalgutkar, D. Walker, D. Dalvie, C. Prakash, V. Alf, *Metabolism, Pharmacokinetics and Toxicity of Functional Groups: Impact of Chemical Building Blocks on ADMET*, (Ed.: D. A. Smith), RSC Publishing, Cambridge, **2010**.
- [4] M. Fung, A. Thornton, K. Mybeck, *Drug Inf. J.* **2001**, *35*, 293–317.
- [5] G. A. Patani, E. J. LaVoie, *Chem. Rev.* **1996**, *96*, 3147–3176; C. W. Thornber, *Chem. Soc. Rev.* **1979**, *8*, 563.
- [6] O. N. Ventura, J. B. Rama, L. Turi, J. J. Dannenberg, *J. Am. Chem. Soc.* **1993**, *115*, 5754–5761.
- [7] A. Mai in *The Chemistry of Hydroxylamines, Oximes and Hydroxamic Acids, Volume 2, Part 1*, (Patai's Chemistry of Functional Groups Series), (Eds.: Z. Rappoport, J. F. Liebman), Wiley, Hoboken, **2009**, p. 731–806 (Chapter 12).
- [8] T. Emery in *Advances in Enzymology and Related Areas of Molecular Biology, Volume 35*, (Ed.: A. Meister), Wiley, Hoboken, **1971**, pp. 135–185.
- [9] E. M. F. Muri, M. J. Nieto, R. D. Sindelar, J. S. Williamson, *Curr. Med. Chem.* **2002**, *9*, 1631–1653.
- [10] L. Bauer, O. Exner, *Angew. Chem.* **1974**, *86*, 419–428; *Angew. Chem. Int. Ed. Engl.* **1974**, *13*, 376–384.
- [11] S. Böhm, O. Exner, *Org. Biomol. Chem.* **2003**, *1*, 1176–1180.
- [12] J. B. Summers, H. Mazdiyasi, J. H. Holms, J. D. Ratajczyk, R. D. Dyer, G. W. Carter, *J. Med. Chem.* **1987**, *30*, 574–580.
- [13] J. B. Summers, B. P. Gunn, J. G. Martin, H. Mazdiyasi, A. O. Stewart, P. R. Young, A. M. Goetze, J. B. Bouska, R. D. Dyer, *J. Med. Chem.* **1988**, *31*, 3–5.
- [14] G. J. Mulder, J. H. Meerman, *Environ. Health Perspect.* **1983**, *49*, 27–32.
- [15] S. D. Barrett, A. J. Bridges, D. T. Dudley, A. R. Saltiel, J. H. Fergus, C. M. Flamme, A. M. Delaney, M. Kaufman, S. LePage, W. R. Leopold, S. A. Przybranowski, J. Sebolt-Leopold, K. Van Becelaere, A. M. Doherty, R. M. Kennedy, D. Marston, W. A. Howard, Jr., Y. Smith, J. S. Warmus, H. Tecle, *Bioorg. Med. Chem. Lett.* **2008**, *18*, 6501–6504.
- [16] W. Froestl, S. J. Mickel, R. G. Hall, G. von Sprecher, D. Strub, P. A. Bauermann, F. Brugger, C. Gentsch, J. Jaekel, *J. Med. Chem.* **1995**, *38*, 3297–3312.
- [17] R. G. Franz, *AAPS PharmSci* **2001**, *3*, 1–13.
- [18] J. C. Watkins, P. Krosgaard-Larsen, T. Honoré, *Trends Pharmacol. Sci.* **1990**, *11*, 25–33.
- [19] D. I. B. Kerr, J. Ong, R. H. Prager, B. D. Gynther, D. R. Curtis, *Brain Res.* **1987**, *405*, 150–154.
- [20] D. R. Curtis, J. C. Watkins, *J. Physiol.* **1963**, *166*, 1–14.
- [21] D. I. B. Kerr, J. Ong, *Med. Res. Rev.* **1992**, *12*, 593–636.
- [22] M. J. Drysdale, M. C. Pritchard, D. C. Horwell, *J. Med. Chem.* **1992**, *35*, 2573–2581.
- [23] D. D. Woods, P. Fildes, *Chem. Ind.* **1940**, *59*, 133; D. D. Woods, *Br. J. Exp. Pathol.* **1940**, *21*, 74–90.
- [24] P. H. Bell, R. O. Roblin, *J. Am. Chem. Soc.* **1942**, *64*, 2905–2917.
- [25] J. F. King in *The Chemistry of Sulphonic Acids, Esters and their Derivatives*, (Patai's Chemistry of Functional Groups Series), (Eds.: S. Patai, Z. Rappoport), Wiley, Chichester, **1991**, pp. 249–259.
- [26] Y. K. Yee, P. R. Bernstein, E. J. Adams, F. J. Brown, L. A. Cronk, K. C. Hebbel, E. P. Vacek, R. D. Krell, D. W. Snyder, *J. Med. Chem.* **1990**, *33*, 2437–2451.
- [27] D. E. Uehling, K. H. Donaldson, D. N. Deaton, C. E. Hyman, E. E. Sugg, D. G. Barrett, R. G. Hughes, B. Reitter, K. K. Adkison, M. E. Lancaster, F. Lee, R. Hart, M. A. Paulik, B. W. Sherman, T. True, C. Cowan, *J. Med. Chem.* **2002**, *45*, 567–583.
- [28] Y. Ducharme, M. Blouin, M. C. Carriere, A. Chateaufneuf, B. Cote, D. Denis, R. Frenette, G. Greig, S. Kargman, S. Lamontagne, E. Martins, F.

- Nantel, G. O'Neill, N. Sawyer, K. M. Metters, R. W. Friesen, *Bioorg. Med. Chem. Lett.* **2005**, *15*, 1155–1160.
- [29] R. J. Herr, *Bioorg. Med. Chem.* **2002**, *10*, 3379–3393.
- [30] L. Myznikov, A. Hrabalek, G. Koldobskii, *Chem. Heterocycl. Compd.* **2007**, *43*, 1–9.
- [31] J. M. McManus, R. M. Herbst, *J. Org. Chem.* **1959**, *24*, 1643–1649.
- [32] G. Costantino, K. Maltoni, M. Marinozzi, E. Camaioni, L. Prezeau, J.-P. Pin, R. Pellicciari, *Bioorg. Med. Chem.* **2001**, *9*, 221–227.
- [33] F. H. Allen, C. R. Groom, J. W. Liebeschuetz, D. A. Bardwell, T. S. G. Olsson, P. A. Wood, *J. Chem. Inf. Model.* **2012**, *52*, 857–866.
- [34] C. Hansch, A. Leo, *Exploring QSAR: Fundamentals and Applications in Chemistry and Biology*, American Chemical Society, Washington DC, **1995**.
- [35] P. W. Kenny, *J. Chem. Inf. Mod.* **2009**, *49*, 1234–1244.
- [36] A. F. Tominey, P. H. Docherty, G. M. Rosair, R. Quenardelle, A. Kraft, *Org. Lett.* **2006**, *8*, 1279–1282; L. Peters, R. Frohlich, A. S. F. Boyd, A. Kraft, *J. Org. Chem.* **2001**, *66*, 3291–3298.
- [37] P. B. Timmermans, P. C. Wong, A. T. Chiu, W. F. Herblin, P. Benfield, D. J. Carini, R. J. Lee, R. W. Wexler, J. A. Saye, R. D. Smith, *Pharmacol. Rev.* **1993**, *45*, 205–251.
- [38] T. J. Murphy, R. W. Alexander, K. K. Griendling, M. S. Runge, K. E. Bernstein, *Nature* **1991**, *351*, 233–236.
- [39] D. J. Carini, J. V. Duncia, P. E. Aldrich, A. T. Chiu, A. L. Johnson, M. E. Pierce, W. A. Price, J. B. Santella, G. J. Wells, *J. Med. Chem.* **1991**, *34*, 2525–2547.
- [40] K. Noda, Y. Saad, A. Kinoshita, T. P. Boyle, R. M. Graham, A. Husain, S. S. Karnik, *J. Biol. Chem.* **1995**, *270*, 2284–2289.
- [41] R. W. Wexler, W. J. Greenlee, J. D. Irvin, M. R. Goldberg, K. Prendergast, R. D. Smith, P. B. M. W. M. Timmermans, *J. Med. Chem.* **1996**, *39*, 625–656.
- [42] T. Naka, K. Kubo, *Curr. Pharm. Des.* **1999**, *5*, 453–472.
- [43] Y. Kohara, K. Kubo, E. Imamiya, T. Wada, Y. Inada, T. Naka, *J. Med. Chem.* **1996**, *39*, 5228–5235.
- [44] C. A. Lipinski, E. F. Fieser, R. J. Korst, *Quant. Struct.-Act. Relat.* **1991**, *10*, 109–117.
- [45] A. R. Saltiel, J. M. Olefsky, *Diabetes* **1996**, *45*, 1661–1669.
- [46] B. R. Henke, S. G. Blanchard, M. F. Brackeen, K. K. Brown, J. E. Cobb, J. L. Collins, W. W. Harrington, M. A. Hashim, E. A. Hull-Ryde, I. Kaldor, S. A. Kliewer, D. H. Lake, L. M. Leesnitzer, J. M. Lehmann, J. M. Lenhard, L. A. Orband-Miller, J. F. Miller, R. A. Mook, S. A. Noble, W. Oliver, D. J. Parks, K. D. Plunket, J. R. Szewczyk, T. M. Willson, *J. Med. Chem.* **1998**, *41*, 5020–5036.
- [47] C. Zhou, C. Tang, E. Chang, M. Ge, S. Lin, E. Cline, C. P. Tan, Y. Feng, Y.-P. Zhou, G. J. Eiermann, A. Petrov, G. Salituro, P. Meinke, R. Mosley, T. E. Akiyama, M. Einstein, S. Kumar, J. Berger, A. D. Howard, N. Thornberry, S. G. Mills, L. Yang, *Bioorg. Med. Chem. Lett.* **2010**, *20*, 1298–1301; J. C. Medina, J. B. Houze, *Annu. Rep. Med. Chem.* **2008**, *43*, 75–85.
- [48] C. C. Blad, C. Tang, S. Offermanns, *Nat. Rev. Drug Discovery* **2012**, *11*, 603–619.
- [49] S. Sasaki, S. Kitamura, N. Negoro, M. Suzuki, Y. Tsujihata, N. Suzuki, T. Santou, N. Kanzaki, M. Harada, Y. Tanaka, M. Kobayashi, N. Tada, M. Funami, T. Tanaka, Y. Yamamoto, K. Fukatsu, T. Yasuma, Y. Momose, *J. Med. Chem.* **2011**, *54*, 1365–1378; S. Mikami, S. Kitamura, N. Negoro, S. Sasaki, M. Suzuki, Y. Tsujihata, T. Miyazaki, R. Ito, N. Suzuki, J. Miyazaki, T. Santou, N. Kanzaki, M. Funami, T. Tanaka, T. Yasuma, Y. Momose, *J. Med. Chem.* **2012**, *55*, 3756–3776.
- [50] R. Alvarez-Sánchez, F. Montavon, T. Hartung, A. Pähler, *Chem. Res. Toxicol.* **2006**, *19*, 1106–1116.
- [51] H. Bräuner-Osborne, J. Egebjerg, E. Ø. Nielsen, U. Madsen, P. Krosgaard-Larsen, *J. Med. Chem.* **2000**, *43*, 2609–2645.
- [52] P. Krosgaard-Larsen, G. A. R. Johnston, D. R. Curtis, C. J. A. Game, R. M. McCulloch, *J. Neurochem.* **1975**, *25*, 803–809.
- [53] P. Krosgaard-Larsen, G. A. Johnston, D. Lodge, D. R. Curtis, *Nature* **1977**, *268*, 53–55.
- [54] B. Frølund, A. T. Jørgensen, L. Tagmose, T. B. Stensbøl, H. T. Vestergaard, C. Engblom, U. Kristiansen, C. Sanchez, P. Krosgaard-Larsen, T. Liljefors, *J. Med. Chem.* **2002**, *45*, 2454–2468; B. Frølund, L. S. Jensen, L. Guanda-
lini, C. Canillo, H. T. Vestergaard, U. Kristiansen, B. Nielsen, T. B. Stensbøl, C. Madsen, P. Krosgaard-Larsen, T. Liljefors, *J. Med. Chem.* **2005**, *48*, 427–439.
- [55] C. G. Jørgensen, R. P. Clausen, K. B. Hansen, H. Bräuner-Osborne, B. Nielsen, M. Bjørn, J. Kehler, P. Krosgaard-Larsen, U. Madsen, *Org. Biomol. Chem.* **2007**, *5*, 463–471; L. Bunch, P. Krosgaard-Larsen, U. Madsen, *J. Org. Chem.* **2002**, *67*, 2375–2377; M. B. Hermit, J. R. Greenwood, B. Nielsen, L. Bunch, C. G. Jørgensen, H. T. Vestergaard, T. B. Stensbøl, C. Sanchez, P. Krosgaard-Larsen, U. Madsen, H. Bräuner-Osborne, *Eur. J. Pharmacol.* **2004**, *486*, 241–250.
- [56] G. V. Perez, A. L. Perez, *J. Chem. Educ.* **2000**, *77*, 910.
- [57] D. Stefanidis, S. Cho, S. Dhe-Paganon, W. P. Jencks, *J. Am. Chem. Soc.* **1993**, *115*, 1650–1656.
- [58] J. Qiu, S. H. Stevenson, M. J. O'Beirn, R. B. Silverman, *J. Med. Chem.* **1999**, *42*, 329–332.
- [59] I. Nicolaou, C. Zika, V. J. Demopoulos, *J. Med. Chem.* **2004**, *47*, 2706–2709.
- [60] J. Avila, J. J. Lucas, M. A. R. Perez, F. Hernandez, *Physiol. Rev.* **2004**, *84*, 361–384.
- [61] L. Claisen, *Justus Liebigs Ann. Chem.* **1894**, *281*, 306–313; L. Claisen, *Justus Liebigs Ann. Chem.* **1896**, *291*, 25–137.
- [62] M. Ito, R. West, *J. Am. Chem. Soc.* **1963**, *85*, 2580–2584.
- [63] T. S. Elliott, A. Slowey, Y. Ye, S. J. Conway, *Med. Chem. Commun.* **2012**, *3*, 735–751.
- [64] W. A. Kinney, N. E. Lee, D. T. Garrison, E. J. Podlesny, J. T. Simmonds, D. Bramlett, R. R. Notvest, D. M. Kowal, R. P. Tasse, *J. Med. Chem.* **1992**, *35*, 4720–4726.
- [65] W. A. Kinney, M. Abou-Gharbia, D. T. Garrison, J. Schmid, D. M. Kowal, D. R. Bramlett, T. L. Miller, R. P. Tasse, M. M. Zaleska, J. A. Moyer, *J. Med. Chem.* **1998**, *41*, 236–246.
- [66] J. J. Kulagowski, R. Baker, N. R. Curtis, I. M. Mawer, A. M. Moseley, M. P. Ridgill, M. Rowley, I. Stansfield, P. D. Leeson, *J. Med. Chem.* **1994**, *37*, 1402–1405.
- [67] M. Rowley, P. D. Leeson, G. I. Stevenson, A. M. Moseley, I. Stansfield, I. Sanderson, L. Robinson, R. Baker, J. A. Kemp, *J. Med. Chem.* **1993**, *36*, 3386–3396.
- [68] A. J. Duplantier, S. L. Becker, M. J. Bohanon, K. A. Borzilleri, B. A. Chrunyk, J. T. Downs, L.-Y. Hu, A. El-Kattan, L. C. James, S. Liu, J. Lu, N. Maklad, M. N. Mansour, S. Mente, M. A. Piotrowski, S. M. Sakya, S. Sheehan, S. J. Steyn, C. A. Strick, V. A. Williams, L. Zhang, *J. Med. Chem.* **2009**, *52*, 3576–3585.
- [69] I. M. Mawer, J. J. Kulagowski, P. D. Leeson, S. Grimwood, G. R. Marshall, *Bioorg. Med. Chem. Lett.* **1995**, *5*, 2643–2648.
- [70] B. J. L. Royle, *Chem. Rev.* **1995**, *95*, 1981–2001; D. Tejedor, F. Garcia-Tellado, *Org. Prep. Proc. Int.* **2004**, *36*, 33.
- [71] T. P. C. Mulholland, R. Foster, D. B. Haydock, *J. Chem. Soc. Perkin Trans. 1* **1972**, 2121–2128.
- [72] A. Zall, D. Kieser, N. Höttecke, E. C. Naumann, B. Thomaszewski, K. Schneider, D. T. Steinbacher, R. Schubeneil, S. Masur, K. Baumann, B. Schmidt, *Bioorg. Med. Chem.* **2011**, *19*, 4903–4909.
- [73] K. Hiraga, *Chem. Pharm. Bull.* **1965**, *13*, 1300–1306.
- [74] C. Ballatore, J. H. Soper, F. Piscitelli, M. James, L. Huang, O. Atasoylu, D. M. Huryn, J. Q. Trojanowski, V. M. Lee, K. R. Brunden, A. B. Smith, *J. Med. Chem.* **2011**, *54*, 6969–6983.
- [75] R. P. Dickinson, K. N. Dack, C. J. Long, J. Steele, *J. Med. Chem.* **1997**, *40*, 3442–3452.
- [76] W. Q. Yang, X. M. Gao, B. H. Wang, *Med. Res. Rev.* **2003**, *23*, 346–368.
- [77] B. L. Chenard, C. A. Lipinski, B. W. Dominy, E. E. Mena, R. T. Ronau, G. C. Butterfield, L. C. Marinovic, M. Pagnozzi, T. W. Butler, T. Tsang, *J. Med. Chem.* **1990**, *33*, 1077–1083; C. A. Lipinski, B. L. Chenard, *Pestic. Sci.* **1990**, *29*, 227–240.
- [78] N. Pemberton, H. Graden, E. Evertsson, E. Bratt, M. Lepistö, P. Johanneson, P. H. Svensson, *ACS Med. Chem. Lett.* **2012**, *3*, 574–578.

Received: December 19, 2013

Published online on January 29, 2013